Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has provided a corporate and operational update highlighting continued progress in its clinical development program, manufacturing activities, regulatory initiatives, financing strategy, and commercialization efforts. The company reported positive six-month results from its First-in-Human (FIH) study, which support advancement to Group Two clinical surgeries, and announced the completion of a next-generation accommodating intraocular lens design, the Ocumetics Lens.
Six-month follow-up data from Group One patients enrolled in the FIH study demonstrated encouraging safety and performance outcomes. The surgical team reported successful implantation procedures and favorable post-operative outcomes. The study continues to achieve its primary objectives related to safety, lens delivery, and distance vision correction. Anecdotally, patients have reported meaningful improvements in vision and quality of life, including one individual previously considered legally blind who is now qualified to drive.
Based on these positive clinical outcomes, Ocumetics has advanced to the second group of its FIH study (Group Two), representing another significant milestone toward commercialization. Group Two surgeries remain on track for Q3 2026 in Mexico City under the leadership of Principal Investigator Dr. Raphael Vasquez. Patients will receive the redesigned Ocumetics Lens delivered with the company's updated lens delivery system.
Ocumetics has completed development of its next-generation solid-state accommodating intraocular lens, which incorporates significant advancements intended to improve manufacturability, surgical handling, long-term reliability, and accommodative performance. The redesigned lens features a simplified one-piece architecture, enhanced accommodative performance, improved manufacturing consistency, and elimination of internal interface materials—no air, water, or oil. Manufacturing of this lens has commenced with the company's German manufacturing partner, Amiplant GmbH. Upcoming activities include finalization of manufacturing, product verification, sterilization, packaging, and release of clinical inventory ahead of the planned Q3 2026 surgeries.
The company has successfully completed all regulatory requirements necessary to proceed to Group Two patient enrollment. Working closely with clinical investigators, ethics committees, and regulatory consultants, Ocumetics has completed the regulatory processes required to advance the study. Upon completion of manufacturing and product release activities, patient recruitment and surgical scheduling will commence.
To support completion of its FIH clinical study and prepare for subsequent regulatory submissions, Ocumetics has launched a financing initiative intended to fund the next phase of clinical development while supporting manufacturing, regulatory, and commercialization activities. Proceeds are expected to be used to complete Group Two FIH surgeries in Mexico City, finalize manufacturing and quality verification of clinical lenses, complete sterilization and packaging activities, advance regulatory and quality assurance programs, and continue strategic partnership and commercialization initiatives.
Strategic discussions continue with four of the world's seven largest ophthalmic companies regarding future partnership and commercialization opportunities. To date, management has met with representatives from these companies to introduce the Ocumetics technology platform. Based on encouraging feedback, several organizations have expressed interest in reviewing additional clinical data following completion of Group Two surgeries, with follow-up discussions tentatively scheduled for early Q4 2026.
With positive six-month clinical data, completion of the next-generation lens design, manufacturing underway, regulatory milestones achieved, and strategic commercialization discussions continuing with leading global ophthalmic companies, Ocumetics believes it is well positioned to execute the next phase of its clinical development strategy. Management remains focused on successfully completing Group Two FIH surgeries, advancing regulatory initiatives, and continuing to build strategic relationships that support the long-term commercialization of the Ocumetics Lens.
